Healthcare >> CEO Interviews >> August 6, 2001
PETER J. SCHIED joined Adolor Corporation in early 1997 as Vice
President, Chief Financial Officer and Corporate Secretary. At Adolor,
Mr. Schied has successfully directed the company's initial public
offering and private financings. Prior to joining Adolor, Mr. Schied
served as Vice President and Chief Financial officer of Transcell
Technologies from 1992-1997. Prior to joining Transcell, Mr. Schied was
the CFO of Greenwich Pharmaceutical Inc. from 1988-1991. Previously, Mr.
Schied held several progressively more responsible financial positions
in the pharmaceutical and healthcare industry, including Vice President
and Controller of Foster Medical Corporation, Vice President, Finance,
of the International Division of Rorer Group and Assistant Controller of
the International Division of Bristol-Myers Company. He received his BS
in Engineering in 1967 and his MBA in Finance and International Business
in 1971 from Drexel University. Mr. Schied holds one US patent on a
class of carbohydrate compounds. Profile
JOHN J. FARRAR was recruited as President and Chief Executive Officer of
Adolor Corporation by its founding investors in October 1994. Prior to
joining Adolor, Dr. Farrar served as Senior vice President, Biological
Research, at Sterling Winthrop Pharmaceuticals Research Division from
1987-1994. Prior to joining Eastman Pharmaceuticals and Sterling
Winthrop, Dr. Farrar held a series of research management positions at
Hoffman-LaRoche from 1982-1987. From 1972-1982, Dr. Farrar held
positions of Staff Fellow, Senior Staff Fellow and Research
Microbiologist at the National Institutes of Health. Dr. Farrar received
his BA in Zoology in 1966 and his MS in Microbiology in 1968 from Miami
University in Oxford, Ohio. Dr. Farrar received a Doctorate in
Microbiology/Immunology from the University of Notre Dame in 1972. Dr.
Farrar has published 70 full-length papers and reviews on the regulation
of the immune response by antigen non-specific regulatory factors. Profile
introduce yourselves, tell us about your experience and involvement with
Adolor and any other industry experience you feel is
